Abstract
Aims l-Carnitine exerts an important role by facilitating the mitochondrial transport of fatty acids, but is also a scavenger of free radicals, protecting cells from oxidative damage. Phenylketonuria (PKU), an inborn error of phenylalanine (Phe) metabolism, is currently treated with a special diet consisting of severe restriction of protein-enriched foods, therefore potentially leading to l-carnitine depletion. The aim of this study was to determine l-carnitine levels and oxidative stress parameters in blood of two groups of PKU patients, with good and poor adherence to treatment. Methods Treatment of patients consisted of a low protein diet supplemented with a synthetic amino acids formula not containing Phe, l-carnitine, and selenium. l-Carnitine concentrations and the oxidative stress parameters thiobarbituric acid reactive species (TBARS) and total antioxidant reactivity (TAR) were measured in blood of the two groups of treated PKU patients and controls. Results We verified a significant decrease of serum l-carnitine levels in patients who strictly adhered to the diet, as compared to controls and patients who did not comply with the diet. Furthermore, TBARS measurement was significantly increased and TAR was significantly reduced in both groups of phenylketonuric patients relatively to controls. We also found a significant negative correlation between TBARS and l-carnitine levels and a significant positive correlation between TAR and l-carnitine levels in well-treated PKU patients. Conclusions Our results suggest that l-carnitine should be measured in plasma of treated PKU patients, and when a decrease of this endogenous component is detected in plasma, supplementation should be considered as an adjuvant therapy.
Similar content being viewed by others
References
Artuch R, Colome C, Sierra C, Brandi N, Lambruschini N, Campistol J, Ugarte D, Vilaseca MA (2004) A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem 37:198–203. doi:10.1016/j.clinbiochem.2003.10.017
Bahl JJ, Bressler R (1987) The pharmacology of l-carnitine. Annu Rev Pharmacol Toxicol 24:257–277. doi:10.1146/annurev.pa.27.040187.001353
Bertelli A, Conte A, Ronca G (1994) l-propyonil carnitine protects erythrocytes and low density lipoproteins against peroxidation. Drugs Exp Clin Res 20:191–197
Böhles H, Ullrich K, Endres W, Behbehani AW, Wendel U (1991) Inadequate iron availability as a possible cause of low serum l-carnitine concentrations in patients with phenylketonuria. Eur J Pediatr 150:425–428. doi:10.1007/BF02093725
Bremer J (1983) Carnitine metabolism and functions. Physiol Rev 63:1420–1480
Brown GC (1999) Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1411:351–369. doi:10.1016/S0005-2728(99)00025-0
Colome C, Sierra C, Vilaseca MA (2000) Congenital errors of metabolism: cause of oxidative stress? Med Clin 115:111–117
De Sousa C, English NR, Stacey TE, Chalmers RA (1990) Measurement of l-carnitine and acylcarnitines in body fluids and tissues in children and in adults. Clin Chim Acta 187:317–328. doi:10.1016/0009-8981(90)90117-B
Di Giacomo C, Latteri F, Fichera C, Sorrenti V, Campisi A, Castorina C, Russo A, Pinturo R, Vanella A (1993) Effect of acetyl-l-l-carnitine on lipid peroxidation and xanthine oxidase activity in rat skeletal muscle. Neurochem Res 18:1157–1162. doi:10.1007/BF00978367
Ercal N, Aykin-Burns N, Gurer-Orhan H, Mcdonald JD (2002) Oxidative stress in a phenylketonuria animal model. Free Radic Biol Med 32:906–911. doi:10.1016/S0891-5849(02)00781-5
Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186:407–421. doi:10.1016/0076-6879(90)86134-H
Fariello RG, Calabrese F (1988) Prevention of ischemia induced increase in MDA by acetyl carnitine. Ann Neurol 24:114–118
Ferrari R, Ciampalini G, Agnoletti G, Cargnoni A, Ceconi C, Visioli O (1988) Effect of l-carnitine derivatives on heart mitochondrial damage induced by lipid peroxidation. Pharmacol Res Commun 20:125–132. doi: 10.1016/S0031-6989(88)80005-5
Fritz IB, Arrigoni-Martelli E (1993) Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends Pharmacol Sci 14:355–360. doi:10.1016/0165-6147(93)90093-Y
Giovanini M, Verduci E, Salvatici E, Fiori L, Riva E (2007) Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis 30:145–152. doi:10.1007/s10545-007-0552-8
Gülçin I (2006) Antioxidant and antiradical activities of l-carnitine. Life Sci 78:803–811. doi:10.1016/j.lfs.2005.05.103
Halliwell B, Gutteridge JMC (2001) Oxidative stress: adaptation, damage, repair and death. In: Halliwell B, Gutteridge JMC (eds) Free radicals in biology and medicine. Oxford University Press, Oxford, pp 246–350
Hendriksz CJ, Walter JH (2004) Update on phenylketonuria. Curr Paediatr 14:400–406. doi:10.1016/j.cupe.2004.05.003
Izgut-Uysal VN, Agac A, Derin N (2001) Effect of carnitine on stress-induced lipid peroxidation in rat gastric mucosa. J Gastroenterol 36:231–236. doi:10.1007/s005350170108
Koudelova J, Mourek J, Drahota Z, Rauchova H (1994) Protective effect of carnitine on lipoperoxide formation in rat brain. Physiol Res 43:387–389
Kremser K, Stangl H, Pahan K, Singh I (1995) Nitric oxide regulates peroxisomal enzyme activities. Eur J Clin Chem Clin Biochem 33:763–774
Lissi E, Salim-Hanna M, Pascual C, Del Castillo MD (1995) Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence measurements. Free Radic Biol Med 18:153–158. doi:10.1016/0891-5849(94)00117-3
Lowitt S, Malone JI, Salem AF, Korthals J, Benford S (1995) Acetyl-l-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metab Clin Exp 44:677–680
Matalon R, Michals-Matalon K, Bhatia G, Grechanina E, Novikov P, McDonald JD, Grady J, Tyring SK, Guttler F (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732–738. doi:10.1007/s10545-006-0395-8
McCaman MW, Robins E (1962) Fluorimetric method for the determination of phenylalanine in serum. J Lab Clin Med 59:885–890
Pons R, De Vivo DC (1995) Primary and secondary carnitine deficiency syndromes. J Child Neurol 2:8–24
Reilly C, Barrett JE, Patterson CM, Tinggi U, Latham SL, Marrinan A (1990) Trace element nutrition status and dietary intake of children with phenylketonuria. Am J Clin Nutr 52:159–165
Schulpis KH, Nounopoulos C, Scarpalezou A, Bouloukos A, Missiou-Tsagarakis S (1990) Serum carnitine level in phenylketonuric children under dietary control in Greece. Acta Paediatr Scand 79:930–934. doi:10.1111/j.1651-2227.1990.tb11354.x
Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1667–1724
Sierra C, Vilaseca MA, Moyano D, Brandi N, Campistol J, Lambruschini N, Cambra FJ, Deulofeu R, Mira A (1998) Antioxidant status in hyperphenylalaninemia. Clin Chim Acta 276:1–9. doi:10.1016/S0009-8981(98)00091-6
Silva-Adaya D, Pérez-De La Cruz V, Herrera-Mundo MN, Mendoza-Macedo K, Villena-Hernández J, Binienda Z, Ali SF, Santamaría A (2008) Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J Neurochem 105:677–689. doi:10.1111/j.1471-4159.2007.05174.x
Sirtori LR, Dutra-Filho CS, Fitarelli D, Sitta A, Haeser A, Barschak AG, Wajner M, Coelho DM, Llesuy S, Belló-Klein A, Giugliani R, Deon M, Vargas CR (2005) Oxidative stress in patients with phenylketonuria. Biochim Biophys Acta 1740:68–73
Sitta A, Barschak AG, Deon M, Terroso T, Pires R, Giugliani R, Dutra-Filho CS, Wajner M, Vargas CR (2006) Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis 21:287–296. doi:10.1007/s11011-006-9035-0
Stanley CA (2004) l-carnitine deficiency disorders in children. Ann NY Acad Sci 1033:42–51. doi:10.1196/annals.1320.004
Start K (1998) Treating phenylketonuria by a phenylalanine-free diet. Prof Care Mother Child 8:109–110
van Backel MME, Printzen G, Wermuth B, Wiesmann UN (2000) Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients. Am J Clin Nutr 72:976–981
Vilaseca MA, Briones P, Ferrer I, Campistol J, Riverola A, Castillo P, Ramon F (1993) Controlled diet in phenylketonuria may cause serum l-carnitine deficiency. J Inherit Metab Dis 16:101–104. doi:10.1007/BF00711322
Virmani A, Binienda Z (2004) Role of l-carnitine esters in brain neuropathology. Mol Aspects Med 25:533–539. doi:10.1016/j.mam.2004.06.003
Acknowledgments
This work was supported in part by grants from FAPERGS, CNPq, and FIPE/HCPA-Brazil.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sitta, A., Barschak, A.G., Deon, M. et al. l-Carnitine Blood Levels and Oxidative Stress in Treated Phenylketonuric Patients. Cell Mol Neurobiol 29, 211–218 (2009). https://doi.org/10.1007/s10571-008-9313-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-008-9313-y